Adolescent Major Depressive Disorder
Conditions
Interventions
a-iTBS group:a-iTBS intervention
Sponsors
Affiliated Kangning Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 12-18 years, regardless of gender; 2. Meeting the diagnostic criteria for depressive disorders according to DSM-V; 3. Right-handed; 4. HAMD-17 score >=17 at screening; 5. Normal indicators in electrocardiogram (ECG) and routine blood test results; 6. If subjects are taking medication, only those taking sertraline, fluoxetine or escitalopram are included; 7. Willing to actively cooperate with treatment after fully understanding the safety of TMS, and providing signed informed consent by both the subject and their guardian.
Exclusion criteria
Exclusion criteria: 1. Individuals with a history of severe somatic diseases or depression induced by other active substances and non-dependent substances; 2. Those with metal or electronic implants in the body, such as intracranial metal objects, cochlear implants, cardiac pacemakers, stents, or other metal foreign bodies; 3. Patients previously or currently diagnosed with severe mental disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic attacks, or eating disorders; 4. Individuals at risk of epileptic seizures, including those with a history of intracranial diseases, head trauma, alcoholism, abnormal EEG findings, MRI evidence of structural brain abnormalities, or a family history of epilepsy; those with a history of cranial surgery deemed unsuitable for participation by the investigator; 5. Those who received modified electroconvulsive therapy (MECT) within 6 months prior to enrollment; 6. Those with psychotic symptoms requiring concomitant antipsychotic medication; 7. Patients who participated in other interventional clinical trials within 3 months; 8. Claustrophobia or other contraindications to MRI; 9. Other conditions considered by the investigator to be unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HAMD-17 score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurophysiological indices derived from multimodal neuroimaging;Scores on other psychological and clinical symptom-related scales;Behavioral and cognitive indices;Neurobiochemical indices;Scores of the Adverse Event Record Form; | — |
Countries
China
Contacts
Public ContactDongsheng Zhou
Affiliated Kangning Hospital of Ningbo University
Outcome results
None listed